 Diabetic Nephropathies
"Diabetic Nephropathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Descriptor ID |
D003928
|
| MeSH Number(s) |
C12.777.419.192 C13.351.968.419.192 C19.246.099.875
|
| Concept/Terms |
Diabetic Nephropathies- Diabetic Nephropathies
- Nephropathies, Diabetic
- Nephropathy, Diabetic
- Diabetic Nephropathy
- Diabetic Kidney Disease
- Diabetic Kidney Diseases
- Kidney Disease, Diabetic
- Kidney Diseases, Diabetic
Diabetic Glomerulosclerosis- Diabetic Glomerulosclerosis
- Kimmelstiel-Wilson Syndrome
- Kimmelstiel Wilson Syndrome
- Syndrome, Kimmelstiel-Wilson
- Kimmelstiel-Wilson Disease
- Kimmelstiel Wilson Disease
- Nodular Glomerulosclerosis
- Glomerulosclerosis, Nodular
- Glomerulosclerosis, Diabetic
- Intracapillary Glomerulosclerosis
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Nephropathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Nephropathies".
This graph shows the total number of publications written about "Diabetic Nephropathies" by people in this website by year, and whether "Diabetic Nephropathies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 1 | 1 | | 1990 | 1 | 1 | 2 | | 1991 | 2 | 0 | 2 | | 1992 | 2 | 1 | 3 | | 1993 | 5 | 2 | 7 | | 1994 | 4 | 0 | 4 | | 1995 | 3 | 3 | 6 | | 1996 | 4 | 0 | 4 | | 1997 | 6 | 3 | 9 | | 1998 | 5 | 1 | 6 | | 1999 | 1 | 1 | 2 | | 2000 | 4 | 1 | 5 | | 2001 | 1 | 0 | 1 | | 2002 | 4 | 2 | 6 | | 2003 | 9 | 1 | 10 | | 2004 | 5 | 3 | 8 | | 2005 | 3 | 1 | 4 | | 2006 | 3 | 1 | 4 | | 2007 | 6 | 1 | 7 | | 2008 | 6 | 2 | 8 | | 2009 | 4 | 15 | 19 | | 2010 | 8 | 2 | 10 | | 2011 | 4 | 3 | 7 | | 2012 | 2 | 0 | 2 | | 2013 | 4 | 2 | 6 | | 2014 | 5 | 3 | 8 | | 2015 | 4 | 2 | 6 | | 2016 | 6 | 0 | 6 | | 2017 | 2 | 0 | 2 | | 2018 | 7 | 2 | 9 | | 2019 | 5 | 1 | 6 | | 2020 | 6 | 2 | 8 | | 2021 | 5 | 0 | 5 | | 2022 | 10 | 0 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetic Nephropathies" by people in Profiles.
-
Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Ruilope LM, Boletis J, Toto R, Umpierrez GE, Wanner C, Wada T, Scott C, Joseph A, Ogbaa I, Roberts L, Scheerer MF, Bakris GL. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results. Nephrol Dial Transplant. 2022 06 23; 37(7):1261-1269.
-
Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 Aug; 102(2):248-260.
-
Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 05 25; 37(6):1014-1023.
-
Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C, Joseph A, Bakris GL, Anker SD. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail. 2022 Jun; 24(6):996-1005.
-
Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, Januzzi JL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure. JACC Heart Fail. 2022 Jul; 10(7):498-507.
-
Cohen S, Sternlicht H, Bakris GL. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Curr Diab Rep. 2022 05; 22(5):213-218.
-
DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 07; 24(7):1197-1205.
-
Chiu N, Aggarwal R, Bakris GL, Pitt B, Bhatt DL. Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. J Am Heart Assoc. 2022 04 05; 11(7):e025079.
-
Liao J, Kang A, Xia C, Young T, Di Tanna GL, Arnott C, Pollock C, Krishnan AV, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Heerspink HJL, Levin A, Neal B, Wheeler DC, Zhang H, Zinman B, Mahaffey KW, Perkovic V, Jardine MJ, Smyth B. The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. Diabetes Metab. 2022 07; 48(4):101331.
-
Stavas J, Gerber D, Coca SG, Silva AL, Johns A, Jain D, Bertram T, Díaz-González de Ferris M, Bakris G. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|